Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study

Pediatric Blood and Cancer

Volumn 60, Issue 7, 2013, Pages 1108-1112

  Skapek, Stephen X ^a   Anderson, James R ^b   Hill, D Ashley ^c   Henry, David ^d   Spunt, Sheri L ^e   Meyer, William ^f   Kao, Simon ^g   Hoffer, Fredric A ^h,i   Grier, Holcombe E ^j   Hawkins, Douglas S ^k   Raney, R Beverly ^l  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ Quality Assurance Review Center   (United States)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Chemotherapy; Desmoid type fibromatosis; Sulindac; Tamoxifen

Indexed keywords

SULINDAC; TAMOXIFEN;

ADOLESCENT; ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILD; DESMOID TUMOR; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CYST; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SCHOOL CHILD; SYSTEMIC THERAPY; TREATMENT DURATION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; FIBROMATOSIS, AGGRESSIVE; HUMANS; MALE; SULINDAC; TAMOXIFEN;

EID: 84878223068     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24457     Document Type: Article

References (31)

1. Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization classification of tumours. Pathology and genetics of soft tissue arnd bone. Lyon: IARC Press; 2002.
2. Pritchard DJ, Nascimento AG, Petersen IA. Local control of extra-abdominal desmoid tumors. J Bone Joint Surg Am 1996;78:848-854.
3. Anthony T, Rodriguez-Bigas MA, Weber TK, et al. Desmoid tumors. J Am Coll Surg 1996;182:369-377.
4. Jabbari S, Andolino D, Weinberg V, et al. Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. Int J Radiat Oncol Biol Phys 2009;75:177-182.
5. Merchant TE, Nguyen D, Walter AW, et al. Long-term results with radiation therapy for pediatric desmoid tumors. Int J Radiat Oncol Biol Phys 2000;47:1267-1271.
6. Smith AJ, Lewis JJ, Merchant NB, et al. Surgical management of intra-abdominal desmoid tumours. Br J Surg 2000;87:608-613.
7. Skapek SX, Ferguson WS, Granowetter L, et al. Vinblastine and methotrexate for desmoid fibromatosis in children: Results of a pediatric oncology group phase II trial. J Clin Oncol 2007;25:501-506.
8. Tsukada K, Church JM, Jagelman DG, et al. Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum 1992;35:29-33.
9. Izes JK, Zinman LN, Larsen CR. Regression of large pelvic desmoid tumor by tamoxifen and sulindac. Urology 1996;47:756-759.
10. Lackner H, Urban C, Kerbl R, et al. Noncytotoxic drug therapy in children with unresectable desmoid tumors. Cancer 1997;80:334-340.
11. Bauernhofer T, Stoger H, Schmid M, et al. Sequential treatment of recurrent mesenteric desmoid tumor. Cancer 1996;77:1061-1065.
12. Soravia C, Berk T, McLeod RS, et al. Desmoid disease in patients with familial adenomatous polyposis. Dis Colon Rectum 2000;43:363-369.
13. Miyaki M, Konishi M, Kikuchi-Yanoshita R, et al. Coexistence of somatic and germ-line mutations of APC gene in desmoid tumors from patients with familial adenomatous polyposis. Cancer Res 1993;53:5079-5082.
14. Alman BA, Li C, Pajerski ME, et al. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997;151:329-334.
15. He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-345.
16. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
17. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-809.
18. Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg 1986;151:230-237.
19. Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-beta expression in extraabdominal fibromatoses: An analysis of 40 cases. Cancer 2006;106:208-213.
20. Woolson RF. Rank-tests and a one-sample logrank test for comparing observed survival-data to a standard population. Biometrics 1981;37:687-696.
21. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556.
22. Skapek SX, Hawk BJ, Hoffer FA, et al. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol 1998;16:3021-3027.
23. Domont J, Salas S, Lacroix L, et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer 2010;102:1032-1036.
24. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008;173:1518-1527.
25. de Camargo VP, Keohan ML, D'Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010;116:2258-2265.
26. Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2003;100:612-620.
27. Meazza C, Bisogno G, Gronchi A, et al. Aggressive fibromatosis in children and adolescents: The Italian experience. Cancer 2010;116:233-240.
28. Buitendijk S, van de Ven CP, Dumans TG, et al. Pediatric aggressive fibromatosis: A retrospective analysis of 13 patients and review of literature. Cancer 2005;104:1090-1099.
29. Lewis JJ, Boland PJ, Leung DH, et al. The enigma of desmoid tumors. Ann Surg 1999;229:866-872; discussion 872-873.
30. Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: A front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009;16:2587-2593.
31. Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: A wait-and-see policy according to tumor presentation. J Clin Oncol 2011;29:3553-3558.